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second patient were within the same 
subgroup, but similarity in nucleotide 
sequences was only 82.5%. This result 
suggests that this patient was infected 
with 2 different virus strains of HRV-A 
and a strain of HRV-C.
Comparison of the HRV-A strains 
with the HRV-C strain showed that 
they belonged to different subgroups 
and had low similarity for nucleotide 
sequences. The second patient had 3 
distinct rhinovirus infections over 3 
months, and each was associated with 
illness requiring hospitalization. Both 
patients had underlying diseases, reac-
tive airway diseases, and repeated epi-
sodes of RTI that may have rendered 
them vulnerable to reinfection, com-
promising their immune responses.
Complete coding sequences of 
HRV-A and HRV-C have been deter-
mined (4,7). However, little is known 
about their involvement in the patho-
genesis of recurrent wheezing in 
young children. According to recent 
reports, HRV-C has been detected in 
hospitalized children with lower RTI 
in the People’s Republic of China (5). 
Possible association of novel infection 
with HRV and exacerbation of asthma 
in children has also been reported (6). 
We report HRV-A and HRV-C co-
infections in conjunction with other 
respiratory viruses, such as RSV, as a 
potential cause of recurrent wheezing 
in infants with acute lower RTIs. Co-
infections with HRV-A and HRV-C 
may contribute to increased virulence 
and subsequent pathogenesis of other 
respiratory viruses. Additional studies 
will be required to further explore the 
clinical role of novel HRVs.
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Extensively  
Drug-Resistant  
Acinetobacter  
baumannii 
To the Editor: In the 1990s, 
patients infected with vancomycin-
resistant Enterococcus faecium were 
successfully treated with new antimi-
crobial drugs. However, it is unlikely 
that new antimicrobial drugs will be 
available in the near future to treat 
patients infected with gram-negative 
pathogens such as Acinetobacter 
baumannii (1). No new antimicrobial 
drugs active against this organism are 
currently in clinical trials (www.clini-
caltrials.gov). We report a patient in-
fected with A. baumannii that lacked 
susceptibility to all commercially 
available antimicrobial drugs.
The patient, a 55-year-old woman, 
had a prolonged stay in an intensive 
care unit at the University of Pitts-
burgh Medical Center (Pittsburgh, 
PA, USA) after undergoing lung trans-
plantation. In the tenth postoperative 
week, ventilator-associated pneumo-
nia developed, which was caused by 
A. baumanni that lacked susceptibil-
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ity to all antimicrobial drugs tested 
except colistin (MIC 0.5 µg/mL). 
Therapy with colistin and tigecycline 
was begun. Colistin was administered 
intravenously and by inhalation. Al-
though the pneumonia showed radio-
graphic response to the antimicrobial 
drug therapy, A. baumannii continued 
to be isolated from respiratory secre-
tions on numerous occasions. Despite 
another course of therapy with colistin 
and cefepime, the patient never re-
covered from respiratory failure. She 
eventually died of sepsis caused by 
vancomycin-resistant E. faecium. An 
A. baumannii isolate obtained just be-
fore she died lacked susceptibility to 
all commercially available antimicro-
bial drugs (Table).
Multidrug-resistant A. bauman-
nii has emerged as a substantial prob-
lem worldwide (2). Such strains are 
typically resistant to all β-lactams 
and fluoroquinolones and require sal-
vage therapy with colistin, amikacin, 
or tigecycline. Unfortunately, notably 
high-level resistance to colistin and 
amikacin was found in the isolate we 
have described (Table). Tigecycline, 
a newly available glycylcycline anti-
microbial drug, showed intermediate 
susceptibility. No randomized trials 
have been performed to specifically 
evaluate combination antimicrobial 
drug therapy for treatment of infection 
with A. baumannii.
Considerable media attention has 
been paid to extensively drug-resistant 
(XDR) strains of Mycobacterium tu-
berculosis (3). Infections with XDR 
strains are extremely difficult to treat 
and pose considerable infection con-
trol issues. We recently proposed that 
gram-negative bacilli lacking suscep-
tibility to all commercially available 
antimicrobial drugs also be referred 
to as XDR because no therapeutic op-
tions are available (4).
Numerous outbreaks of A. bau-
mannii infection have been reported 
worldwide (5). Unfortunately, mul-
tidrug-resistant A. baumannii strains 
have become endemic in some in-
stitutions. Experimental and clini-
cal isolates lacking susceptibility to 
colistin, often considered the drug 
of last resort, are increasingly being 
reported (6–8). Therefore, we alert 
healthcare workers to the need for 
stringent care in adhering to infec-
tion control precautions when caring 
for patients infected with XDR A. 
baumannii. Use of contact isolation 
precautions, enhanced environmen-
tal cleaning, removal of sources of 
infection from the hospital environ-
ment, and prudent use of antimicro-
bial drugs can contribute to control 
of such outbreaks (5). Fortunately, 
no spread of the XDR strain affect-
ing this patient occurred. A crisis is 
looming should XDR A. bauman-
nii become established pathogens in 
hospitals.
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Table. MICs and antimicrobial drug susceptibility for an extensively drug-resistant strain 
of Acinetobacter baumannii*
Drugs MIC, ȝg/mL Interpretation 
Carbapanems 
 Imipenem >32 Resistant
 Meropenem >32 Resistant
Penicillins 
 Ampicillin/sulbactam 32 Resistant
 Piperacillin/tazobactam >256 Resistant
Cephalosporins
 Ceftazidime 48 Resistant
 Cefepime 16 Intermediate
Aminoglycosides 
 Gentamicin >256 Resistant
 Tobramycin >256 Resistant
 Amikacin >256 Resistant
Others
 Ciprofloxacin >32 Resistant
 Tigecycline 2 Intermediate
 Colistin >1,024 Resistant
*Susceptibility testing was performed by using the Etest (AB Biodisk, Solna, Sweden), except for 
colistin, for which the standard agar dilution method was used. Interpretation was according to 
breakpoints provided by the Clinical and Laboratory Standards Institute (CLSI; Wayne, PA, USA). 
No tigecycline breakpoints for Acinetobacter spp. are provided by the CLSI, the European 
Committee on Antimicrobial Susceptibility Testing (Basel, Switzerland), or the US Food and Drug 
Administration (Silver Spring, MD, USA). Breakpoints of the British Society for Antimicrobial 
Chemotherapy (Birmingham, UK) are indicated for tigecycline. 
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Cryptosporidium 
Pig Genotype II in 
Immunocompetent 
Man
To the Editor: Protozoan para-
sites from the genus Cryptosporidium 
have been described as a cause of diar-
rheal disease in immunodeficient and 
immunocompetent humans world-
wide. Although C. hominis and C. 
parvum (cattle genotype) cause most 
infections, humans can be infected by 
several other Cryptosporidium spe-
cies or genotypes: C. meleagridis; C. 
felis; C. canis; C. suis; C. muris; C. 
andersoni; C. hominis monkey geno-
type; C. parvum (mouse genotype); 
and Cryptosporidium rabbit genotype, 
deer genotype, skunk genotype, horse 
genotype, and chipmunk genotype 
I (1–4). Wild and domestic animals 
are sources of infection for humans 
(and other animals) and important 
contributors to contamination of food 
and drinking water; many nonhuman 
Cryptosporidium species or genotypes 
are detected in untreated water (5). We 
examined the diversity of Cryptospo-
ridium spp. in immunocompetent per-
sons in South Bohemia in the Czech 
Republic.
Diarrheal fecal samples (n = 457) 
from 203 anonymous immunocom-
petent patients <69 years of age with 
suspected cryptosporidiosis (at least 
2 samples/patient/3-day period) were 
obtained from local health depart-
ments and public hospitals in South 
Bohemia during 2005–2007. Samples 
were examined for Cryptosporidium 
oocysts by using aniline-carbol-meth-
yl violet staining and light microscopy 
at × 1,000 magnification (6). The mi-
croscopically positive samples were 
confirmed by DNA sequencing of the 
small subunit (SSU) rRNA gene. Total 
DNA was extracted from 200–300 mg 
stool by using the QIAamp DNA Stool 
Mini Kit (QIAGEN, Hilden, Germa-
ny), following the manufacturer’s in-
structions, after previous homogeniza-
tion and disruption of oocysts with the 
Mini-BeadBeater (Biospec Products, 
Bartlesville, OK, USA). An ≈830-bp 
fragment of the SSU rRNA gene was 
amplified by nested PCR according to 
Jiang et al. (7). Purified PCR products 
were sequenced in both directions on an 
ABI3130 sequencer analyzer (Applied 
Biosystems, Foster City, CA, USA) by 
using the secondary PCR primers and 
the BigDye Terminator v3.1 Cycle Se-
quencing Kit (Applied Biosystems). 
Sequences were assembled by using 
Chromas Pro (www.technelysium.
com.au/chromas.html) and aligned 
with reference sequences using Clust-
alX (ftp://ftp-igbmc.u-strasbg.fr/pub/
ClustalX). The BLAST server (www.
ncbi.nlm.nih.gov/BLAST) was used 
for DNA database searches. The SSU 
rRNA gene partial sequences of the 7 
patient isolates have been submitted to 
GenBank (Table).
Of the 203 patients, 7 (3.4%) (6 
children and 1 adult) had positive re-
sults for Cryptosporidium spp. More-
over, all samples obtained from these 
persons during the 3-day period were 
Cryptosporidium spp. positive; par-
tial sequences of the Cryptosporidium 
SSU rRNA gene were obtained from 
all positive samples identifying 3 dif-
ferent species or genotypes of Cryp-
tosporidium. Five were C. parvum 
(bovine genotype), 1 was C. hominis, 
and 1 contained the Cryptosporidium 
pig genotype II (Table). Cryptospo-
ridium pig genotype II was found in 
stool samples from a 29-year-old man 
who also was infected with Giardia 
intestinalis (assemblage A) (data not 
shown).
Only C. parvum (bovine geno-
type), C. hominis, and Cryptospo-
ridium rabbit genotype have been 
implicated in waterborne outbreaks 
of cryptosporidiosis in humans. Fur-
ther studies are needed to determine 
the potential of other cryptosporidia 
of animal origin. Recent genetic and 
biologic characterization studies have 
identified 2 distinct host-adapted 
cryptosporidia in pigs, C. suis and 
Cryptosporidium pig genotype II. 
Furthermore, both above-mentioned 
cryptosporidia have been identified 
in untreated water (8). Pigs could be 
sources of Cryptosporidium water and 
food pollution and a consequent risk 
to public health.
Although human infection with 
C. suis has been previously described 
(9), human infection with Cryptospo-
ridium pig genotype II has been never 
reported. This genotype was found 
in diarrheal stool of 1 adult patient 
in this study. However, onset of di-
arrhea could have been caused by 
co-infection with G. intestinalis (as-
semblage A), which recently also has 
been described in pigs (10). Contact 
with infected animals and ingestion of 
contaminated food or water could be 
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